Is there an M‑protein test or therapy indicated for non‑ischemic dilated cardiomyopathy?

M-Protein Testing in Non-Ischemic Dilated Cardiomyopathy

M-protein testing (serum protein electrophoresis with immunofixation) is indicated in the diagnostic workup of non-ischemic dilated cardiomyopathy to screen for cardiac amyloidosis, which is a secondary cardiomyopathy that can present with a dilated phenotype.

Rationale for M-Protein Testing

The 2016 AHA Scientific Statement explicitly categorizes amyloidosis as a secondary cardiomyopathy that causes myocardial involvement as part of systemic (multiorgan) disease 1. When evaluating patients with apparent non-ischemic dilated cardiomyopathy, excluding infiltrative causes like amyloidosis is critical because:

• Treatment differs fundamentally - amyloidosis requires disease-specific therapy targeting the underlying protein deposition, not just standard heart failure management
• Prognosis varies significantly - untreated cardiac amyloidosis has worse outcomes than other forms of DCM
• Misclassification leads to inappropriate management - treating amyloid cardiomyopathy as idiopathic DCM delays proper therapy

When to Order M-Protein Testing

The ESC guidelines recommend second-level laboratory tests in selected patients to identify specific etiologies, particularly metabolic and syndromic causes, following specialist evaluation 2. Order serum and urine protein electrophoresis with immunofixation when:

• Unexplained restrictive physiology on echocardiography (elevated filling pressures despite preserved or mildly reduced ejection fraction initially)
• Increased left ventricular wall thickness (≥12mm) with low voltage on ECG - classic red flag
• Disproportionate elevation of cardiac biomarkers (troponin, NT-proBNP) relative to degree of systolic dysfunction
• Multisystem involvement - peripheral neuropathy, carpal tunnel syndrome, renal dysfunction, hepatomegaly
• Age >60 years with new-onset heart failure - consider wild-type (senile) amyloidosis

Diagnostic Algorithm

1. First-line screening: Serum free light chains (kappa/lambda ratio) and serum protein electrophoresis with immunofixation
2. If positive or high suspicion persists: 24-hour urine protein electrophoresis with immunofixation
3. Confirm with imaging: Cardiac MRI showing late gadolinium enhancement with characteristic patterns, or nuclear imaging (technetium pyrophosphate scan)
4. Definitive diagnosis: Endomyocardial biopsy with Congo red staining and immunohistochemistry for amyloid typing (if non-invasive testing inconclusive)

Critical Pitfall

Do not assume all dilated ventricles represent primary DCM. The AHA statement emphasizes that secondary cardiomyopathies like amyloidosis must be systematically excluded 1. Missing infiltrative disease means missing the opportunity for disease-modifying therapy (e.g., tafamidis for transthyretin amyloidosis, chemotherapy for AL amyloidosis).

M-Protein as Therapy

There is no therapeutic role for M-protein administration in non-ischemic DCM. The term "M-protein" in clinical practice refers to monoclonal protein detection for diagnosis, not a treatment modality. Current DCM management focuses on guideline-directed medical therapy for heart failure, with emerging stem cell therapies under investigation 3, but no M-protein-based interventions exist.

The evidence base for biomarkers in DCM emphasizes troponin, BNP/NT-proBNP, and high-sensitivity CRP for risk stratification 4, 5, with M-protein testing reserved specifically for excluding amyloidosis as an alternative diagnosis rather than prognosticating idiopathic DCM.